This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Background: Although rivaroxaban has demonstrated consistent drug levels in normal
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Introduction Current evidence indicates that rivaroxaban may be a safe and effective
alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …

Background and aims The association between body mass index (BMI) and clinical
outcomes of patients with non-valvular atrial fibrillation (NVAF) taking oral anticoagulants …